Functional impairment outcomes in clinical trials of different ADHD medications: post hoc responder analyses and baseline subgroup analyses.

European Child & Adolescent Psychiatry
David R CoghillMichael Huss

Abstract

Several recent phase 3 clinical trials of attention-deficit/hyperactivity disorder (ADHD) medications have used the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Here, we assess WFIRS-P response in individual patients in two pivotal trials of lisdexamfetamine dimesylate (LDX) and guanfacine extended release (GXR). We also analysed pooled WFIRS-P data from seven phase 3 studies of ADHD medications to shed light on factors associated with baseline functional impairment. The proportion of patients with a change in WFIRS-P score that exceeded the minimal important difference (MID) criteria for response was greater for LDX than placebo in the Family, Learning and School, and Risky Activities domains, and was greater for GXR than placebo in the Social Activities, Learning and School, and Family domains. Responders had significantly worse baseline scores in all WFIRS-P domains (all p < 0.001) than non-responders. In the pooled analyses, baseline WFIRS-P scores in all domains were significantly worse in participants with oppositional defiant disorder (ODD) than in those without ODD. Having combined type or hyperactive-impulsive type ADHD, being enrolled into a study in Europe, being male and being younger also had m...Continue Reading

References

Jun 2, 2007·The American Journal of Psychiatry·Guilherme PolanczykLuis Augusto Rohde
May 13, 2009·Journal of Child Psychology and Psychiatry, and Allied Disciplines·David CoghillUNKNOWN ADHD European Guidelines Group
Jan 22, 2013·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·David CoghillLiza Squires
Aug 27, 2013·Journal of the American Academy of Child and Adolescent Psychiatry·Jeffrey H NewcornJonathan Rubin
Dec 18, 2013·Journal of the American Academy of Child and Adolescent Psychiatry·Susanna N VisserStephen J Blumberg
Jan 28, 2014·International Journal of Epidemiology·Guilherme V PolanczykLuis A Rohde
May 21, 2014·Journal of the American Academy of Child and Adolescent Psychiatry·David R CoghillLiza A Squires
Nov 28, 2014·Attention Deficit and Hyperactivity Disorders·Mahmut C TarakçıoğluMargaret D Weiss
Dec 3, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Amaia HervasBrigitte Robertson
Oct 3, 2015·BMJ Open·Bradley C JohnstonGihad Nesrallah
Oct 28, 2015·Journal of the American Academy of Child and Adolescent Psychiatry·Timothy E WilensAndrew J Cutler
Feb 13, 2016·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Jeffrey H NewcornBrigitte Robertson
Jul 24, 2018·Journal of Child and Adolescent Psychopharmacology·Margaret WeissAkwete L Adjei

❮ Previous
Next ❯

Citations

Apr 3, 2021·European Child & Adolescent Psychiatry·Livia Balan-Moshe, Doron Gothelf
May 28, 2021·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Trine Wigh ArildskovSøren D Østergaard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.